MX2018011666A - Combinaciones farmaceuticas para el tratamiento de cancer. - Google Patents
Combinaciones farmaceuticas para el tratamiento de cancer.Info
- Publication number
- MX2018011666A MX2018011666A MX2018011666A MX2018011666A MX2018011666A MX 2018011666 A MX2018011666 A MX 2018011666A MX 2018011666 A MX2018011666 A MX 2018011666A MX 2018011666 A MX2018011666 A MX 2018011666A MX 2018011666 A MX2018011666 A MX 2018011666A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- cancer
- pharmaceutical combinations
- inhibitor
- combination therapies
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 abstract 2
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 abstract 2
- 239000012664 BCL-2-inhibitor Substances 0.000 abstract 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 229940079156 Proteasome inhibitor Drugs 0.000 abstract 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 abstract 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 239000003207 proteasome inhibitor Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se relaciona con terapias de combinación para el tratamiento de cánceres, tales como leucemia, linfoma y cáncer de mama triple negativo. La descripción proporciona terapias de combinación de inhibidores de CDK, por ejemplo, un inhibidor de CDK representado por la fórmula (I) o una sal farmacéuticamente aceptable del mismo, junto con un inhibidor de BCL-2 o inhibidor de proteasoma para el tratamiento de cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662314356P | 2016-03-28 | 2016-03-28 | |
PCT/US2017/024618 WO2017172826A1 (en) | 2016-03-28 | 2017-03-28 | Pharmaceutical combinations for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018011666A true MX2018011666A (es) | 2019-07-08 |
Family
ID=59966407
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018011666A MX2018011666A (es) | 2016-03-28 | 2017-03-28 | Combinaciones farmaceuticas para el tratamiento de cancer. |
MX2022011750A MX2022011750A (es) | 2016-03-28 | 2018-09-25 | Combinaciones farmaceuticas para el tratamiento de cancer. |
MX2022002318A MX2022002318A (es) | 2016-03-28 | 2018-09-25 | Combinaciones farmaceuticas para el tratamiento de cancer. |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022011750A MX2022011750A (es) | 2016-03-28 | 2018-09-25 | Combinaciones farmaceuticas para el tratamiento de cancer. |
MX2022002318A MX2022002318A (es) | 2016-03-28 | 2018-09-25 | Combinaciones farmaceuticas para el tratamiento de cancer. |
Country Status (13)
Country | Link |
---|---|
US (4) | US11135198B2 (es) |
EP (1) | EP3436002A4 (es) |
JP (3) | JP7114478B2 (es) |
KR (5) | KR102545392B1 (es) |
CN (1) | CN109689047A (es) |
AU (4) | AU2017241914B2 (es) |
CA (2) | CA3018932C (es) |
IL (2) | IL295472A (es) |
MX (3) | MX2018011666A (es) |
NZ (1) | NZ747404A (es) |
RU (2) | RU2020121147A (es) |
WO (1) | WO2017172826A1 (es) |
ZA (1) | ZA201806819B (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2624981T3 (es) | 2011-07-01 | 2017-07-18 | Dana-Farber Cancer Institute, Inc. | Descubrimiento de una mutación somática en el gen MYD88 en linfoma linfoplasmocitario |
JP7114478B2 (ja) * | 2016-03-28 | 2022-08-08 | プレサージュ バイオサイエンシズ,インコーポレイテッド | 癌の治療のための配合剤 |
US11524009B2 (en) * | 2017-10-31 | 2022-12-13 | Eisai R&D Management Co., Ltd. | Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from BCL2 inhibitors, BCL2/BCLxL inhibitors, and BCLxL inhibitors and methods of use |
CN108261414B (zh) * | 2018-01-11 | 2019-09-06 | 广西师范大学 | 一种治疗肺癌的药物组合物 |
CN108186642B (zh) * | 2018-01-11 | 2019-11-08 | 广西师范大学 | 一种协同起作用治疗肺癌的药物组合物 |
MX2021001764A (es) * | 2018-08-14 | 2021-04-19 | Mei Pharma Inc | Terapia de combinacion. |
WO2020092615A1 (en) * | 2018-11-01 | 2020-05-07 | Oregon Health & Science University | Treatments for venetoclax-resistant and venetoclax-sensitive acute myeloid leukemia |
EP4041239A1 (en) * | 2019-10-08 | 2022-08-17 | Dana-Farber Cancer Institute, Inc. | A pyrazolopyrimidine derivative as a hck inhibitor for use in therapy, in particular myd88 mutated diseases |
IL297960A (en) * | 2020-05-07 | 2023-01-01 | Recurium Ip Holdings Llc | conjunctions |
EP4247806A1 (en) * | 2020-11-19 | 2023-09-27 | MEI Pharma, Inc. | Treatment of kras mutant cancers |
CN113018357A (zh) * | 2021-02-08 | 2021-06-25 | 湖南农业大学 | 茶多酚和帕博西尼联合在制备治疗乳腺癌的制剂中的用途 |
EP4319744A1 (en) * | 2021-04-10 | 2024-02-14 | MEI Pharma, Inc. | Voruciclib dosing regimens and methods of treatment including the same |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2219867A1 (en) * | 1997-10-31 | 1999-04-30 | Jiangping Wu | The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock |
UY26942A1 (es) | 2000-09-20 | 2002-04-26 | Abbott Lab | N-acilsulfonamidas promotoras de la apoptosis |
US7271193B2 (en) | 2002-07-08 | 2007-09-18 | Nicholas Piramal India, Ltd. | Inhibitors of cyclin-dependent kinases and their use |
TWI331034B (en) | 2002-07-08 | 2010-10-01 | Piramal Life Sciences Ltd | Inhibitors of cyclin-dependent kinases and their use |
US7642260B2 (en) | 2003-11-13 | 2010-01-05 | Abbott Laboratories, Inc. | Apoptosis promoters |
US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
US7767684B2 (en) | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
WO2005049593A2 (en) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
US7842815B2 (en) | 2004-06-17 | 2010-11-30 | Infinity Pharmaceuticals, Inc. | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners |
AU2005265131B2 (en) | 2004-06-17 | 2012-02-23 | Infinity Discovery, Inc. | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners |
KR101509440B1 (ko) | 2005-05-12 | 2015-04-07 | 애브비 바하마스 리미티드 | 아폽토시스 촉진제 |
US8624027B2 (en) | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
WO2006127364A1 (en) | 2005-05-24 | 2006-11-30 | Abbott Laboratories | Apoptosis promoters |
US20090142337A1 (en) * | 2006-05-08 | 2009-06-04 | Astex Therapeutics Limited | Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment |
ES2491140T3 (es) | 2006-06-21 | 2014-09-05 | Piramal Enterprises Limited | Derivados de flavona enantioméricamente puros para el tratamiento de trastornos proliferativos y procesos para su preparación |
EP2154971B1 (en) * | 2007-05-15 | 2011-12-28 | Piramal Life Sciences Limited | A synergistic pharmaceutical combination for the treatment of cancer |
US9259399B2 (en) * | 2007-11-07 | 2016-02-16 | Cornell University | Targeting CDK4 and CDK6 in cancer therapy |
US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
NZ593536A (en) | 2008-12-19 | 2013-07-26 | Genentech Inc | Quinoline derivatives and methods of use |
TWI535712B (zh) | 2010-08-06 | 2016-06-01 | 阿斯特捷利康公司 | 化合物 |
CN104220066A (zh) * | 2010-11-19 | 2014-12-17 | 皮拉马尔企业有限公司 | 紫杉醇和cdk抑制剂药物组合物 |
TW201300105A (zh) * | 2011-05-31 | 2013-01-01 | Piramal Life Sciences Ltd | 治療頭頸鱗狀細胞癌之相乘藥物組合物 |
US9241941B2 (en) * | 2012-09-20 | 2016-01-26 | Memorial Sloan-Kettering Cancer Center | Methods for treatment of lymphomas with mutations in cell cycle genes |
NZ709635A (en) | 2013-01-16 | 2019-10-25 | Univ Michigan | Bcl-2bcl-xl inhibitors and therapeutic methods using the same |
US10314842B2 (en) | 2013-12-02 | 2019-06-11 | Cornell University | Methods for treating B cell proliferative disorders |
WO2015130585A1 (en) | 2014-02-28 | 2015-09-03 | Merck Sharp & Dohme Corp. | Method for treating cancer |
EP3148532B1 (en) * | 2014-05-28 | 2021-03-03 | Piramal Enterprises Limited | Pharmaceutical combination comprising a cdk inhibitor and a thioredoxin reductase inhibitor for the treatment of cancer |
DK3179991T3 (da) * | 2014-08-11 | 2021-12-06 | Acerta Pharma Bv | Terapeutiske kombinationer af en btk-inhibitor og en bcl-2-inhibitor |
US9637488B2 (en) * | 2015-01-29 | 2017-05-02 | Fuqiang Ruan | Heterocyclic compounds as inhibitors of class I PI3KS |
JP7114478B2 (ja) * | 2016-03-28 | 2022-08-08 | プレサージュ バイオサイエンシズ,インコーポレイテッド | 癌の治療のための配合剤 |
-
2017
- 2017-03-28 JP JP2018550790A patent/JP7114478B2/ja active Active
- 2017-03-28 US US16/089,276 patent/US11135198B2/en active Active
- 2017-03-28 NZ NZ747404A patent/NZ747404A/en unknown
- 2017-03-28 CA CA3018932A patent/CA3018932C/en active Active
- 2017-03-28 CA CA3103604A patent/CA3103604C/en active Active
- 2017-03-28 RU RU2020121147A patent/RU2020121147A/ru unknown
- 2017-03-28 KR KR1020237002852A patent/KR102545392B1/ko active IP Right Grant
- 2017-03-28 MX MX2018011666A patent/MX2018011666A/es unknown
- 2017-03-28 CN CN201780032783.3A patent/CN109689047A/zh active Pending
- 2017-03-28 KR KR1020237019958A patent/KR102599512B1/ko active IP Right Grant
- 2017-03-28 KR KR1020187030575A patent/KR102275758B1/ko active IP Right Grant
- 2017-03-28 AU AU2017241914A patent/AU2017241914B2/en active Active
- 2017-03-28 EP EP17776498.2A patent/EP3436002A4/en active Pending
- 2017-03-28 WO PCT/US2017/024618 patent/WO2017172826A1/en active Application Filing
- 2017-03-28 KR KR1020237037917A patent/KR20230156443A/ko not_active Application Discontinuation
- 2017-03-28 IL IL295472A patent/IL295472A/en unknown
- 2017-03-28 RU RU2018137687A patent/RU2726367C2/ru active
- 2017-03-28 KR KR1020217021031A patent/KR102494039B1/ko active IP Right Grant
-
2018
- 2018-09-17 IL IL261824A patent/IL261824B2/en unknown
- 2018-09-25 MX MX2022011750A patent/MX2022011750A/es unknown
- 2018-09-25 MX MX2022002318A patent/MX2022002318A/es unknown
- 2018-10-12 ZA ZA2018/06819A patent/ZA201806819B/en unknown
-
2019
- 2019-05-28 US US16/423,216 patent/US20190275004A1/en not_active Abandoned
-
2020
- 2020-02-20 AU AU2020201247A patent/AU2020201247B2/en active Active
-
2021
- 2021-06-03 US US17/337,952 patent/US20210283104A1/en active Pending
- 2021-07-09 US US17/371,774 patent/US20220023261A1/en active Pending
- 2021-11-23 AU AU2021273532A patent/AU2021273532B2/en active Active
-
2022
- 2022-07-27 JP JP2022119166A patent/JP7416872B2/ja active Active
-
2023
- 2023-12-28 JP JP2023223257A patent/JP2024038227A/ja active Pending
-
2024
- 2024-01-11 AU AU2024200194A patent/AU2024200194A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022011750A (es) | Combinaciones farmaceuticas para el tratamiento de cancer. | |
MX2020003939A (es) | Inhibidores de mdm2 y metodos terapeuticos que utilizan los mismos. | |
WO2018086591A8 (zh) | 吡啶胺取代的杂三环化合物、其制法与医药上的用途 | |
GEP20207161B (en) | New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them | |
CA2983481A1 (en) | Janus kinase inhibitor | |
PH12016502354A1 (en) | Pharmaceutical composition | |
MY176235A (en) | Compounds that inhibit mcl-1 protein | |
MD20170016A2 (ro) | Compuşi aminopirimidinici ca inhibitori JAK | |
PH12018500987A1 (en) | Dihydroimidazopyrazinone derivatives useful in the treatment of cancer | |
NZ629456A (en) | Methods for treating cancer using tor kinase inhibitor combination therapy | |
MY198613A (en) | Nitrobenzyl derivatives of anti-cancer agents | |
PH12019501022A1 (en) | Pyrazolopyrimidine compounds and methods of use thereof | |
WO2016133903A3 (en) | Combination therapy for cancer treatment | |
MX2022005298A (es) | Compuestos intermediarios de sintesis de inhibidores de a2a. | |
MX2019015207A (es) | Compuestos para tratar el cancer de ovario. | |
TN2019000210A1 (en) | Antitumoral compounds | |
MX2018005233A (es) | Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer. | |
MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
MX2019015676A (es) | Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento. | |
MX2020005659A (es) | Uso de un inhibidor de parp en el tratamiento del cancer de ovario o cancer de mama resistente a la quimioterapia. | |
PH12017501882A1 (en) | Methods for treating cancer with a stat3 pathway inhibitor and kinase inhibitor | |
NZ732704A (en) | Quinoline carboxamides for use in the treatment of leukemia | |
TW201613570A (en) | Methods for cancer therapy | |
MX2017002544A (es) | Derivados de isoquinolinona utiles en el tratamiento contra el cancer. | |
MX2017002627A (es) | Derivados de polieteres macrociclicos de n-aril-2-amino-4-aril-pir imidina como inhibidores de ftl3 y jak. |